Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Nov 26;62(12):e01353-18.
doi: 10.1128/AAC.01353-18. Print 2018 Dec.

Rifampin Resistance in Staphylococci after Rifaximin Intake for Surgical Prophylaxis in Elective Colorectal Surgery

Emma Padilla  1 , Lluis Oms  2 , Elena Espejo  3 , Laura Gómez  2 , Lurdes Pagespetit  4 , Núria Boada  4 , Feliu Bella  3 , Josefa Pérez  5
Affiliations

Rifampin Resistance in Staphylococci after Rifaximin Intake for Surgical Prophylaxis in Elective Colorectal Surgery

Emma Padilla et al. Antimicrob Agents Chemother. .

Abstract

The aim of our study was to determine whether rifampin resistance emerges in human skin staphylococci after oral intake of rifaximin for surgical prophylaxis. Rifampin-resistant staphylococci appeared on the skin of 32 out of 74 patients (43.2%) two weeks after prophylactic treatment with rifaximin. In all cases, the resistant strains were coagulase-negative staphylococci. The resistance completely reverted after three months. This study shows the emergence of transient resistance to rifampin after rifaximin intake.

Keywords: Staphylococcus; antibiotic resistance; rifampin; rifaximin; surgical prophylaxis.

PubMed Disclaimer

References

    1. Gillis JC, Brogden RN. 1995. Rifaximin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential in conditions mediated by gastrointestinal bacteria. Drugs 49:467–484. doi: 10.2165/00003495-199549030-00009. - DOI - PubMed
    1. Shayto RH, Abou Mrad R, Sharara AI. 2016. Use of rifaximin in gastrointestinal and liver diseases. World J Gastroenterol 22:6638–6651. doi: 10.3748/wjg.v22.i29.6638. - DOI - PMC - PubMed
    1. Adachi JA, DuPont HL. 2006. Rifaximin: a novel nonabsorbed rifamycin for gastrointestinal disorders. Clin Infect Dis 42:541–547. doi: 10.1086/499950. - DOI - PubMed
    1. Tupin A, Gualtieri M, Roquet-Banères F, Morichaud Z, Brodolin K, Leonetti JP. 2010. Resistance to rifampin: at the crossroads between ecological, genomic and medical concerns. Int J Antimicrob Agents 35:519–523. doi: 10.1016/j.ijantimicag.2009.12.017. - DOI - PubMed
    1. Valentin T, Leitner E, Rohn A, Zollner-Schwetz I, Hoenigl M, Salzer HJ, Krause R. 2011. Rifaximin intake leads to emergence of rifampin-resistant staphylococci. J Infect 62:34–38. doi: 10.1016/j.jinf.2010.11.004. - DOI - PubMed

MeSH terms

LinkOut - more resources